Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. reports company news around a clinical-stage oncology pipeline led by evorpacept, an investigational CD47 inhibitor designed to address a cancer immune-evasion signal. Updates commonly cover clinical data presentations, biomarker analyses involving CD47 expression, and studies of evorpacept combinations in HER2-positive cancers, including breast and gastric cancer settings.
The company also reports development activity for ALX2004, an EGFR-targeted antibody-drug conjugate for EGFR-expressing solid tumors. Other recurring updates include quarterly financial results, research and development spending, cash runway commentary, registered offerings of common stock and pre-funded warrants, leadership appointments, investor conference participation, and Nasdaq inducement equity grants.
ALX Oncology (Nasdaq: ALXO) reported exploratory Phase 1b/2 data showing CD47 expression predicts response to investigational CD47 inhibitor evorpacept combined with Ziihera (zanidatamab-hrii) in HER2-positive metastatic breast cancer. In nine centrally confirmed HER2-positive patients the combination produced a 56% confirmed objective response rate and median PFS of 7.4 months. The full biomarker analysis has been submitted for presentation at an upcoming scientific congress and reinforces prior ASPEN-06 gastric cancer findings linking CD47 expression to benefit.
ALX Oncology (Nasdaq: ALXO) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation and fireside chat on January 15, 2026 at 12:00 p.m. PT. A live webcast will be available via the Investors section of ALX Oncology’s website under Events and Presentations. A replay of the webcast will be archived and available for up to 90 days after the fireside chat.
ALX Oncology (Nasdaq: ALXO) announced clinical progress for two investigational therapies. The company dosed the first patient in the Phase 2 ASPEN-09-Breast trial of evorpacept combined with trastuzumab and physician’s choice chemotherapy in HER2-positive metastatic breast cancer post-ENHERTU; an interim analysis is anticipated in Q3 2026. The Phase 1 study of EGFR-targeted ADC ALX2004 advanced to a third dose cohort at 4 mg/kg after no dose-limiting toxicities in the first two cohorts; an initial safety update is expected in 1H 2026.
The ASPEN-09 trial will enroll ~80 patients and use CD47 expression and HER2 ctDNA as biomarkers; primary endpoint is overall response rate (ORR).
ALX Oncology (NASDAQ: ALXO) reported positive Phase 2 investigator‑sponsored data for evorpacept combined with rituximab and lenalidomide (R2) in untreated indolent B‑cell non‑Hodgkin lymphoma presented at ASH 2025.
In 24 frontline patients (14 follicular, 10 marginal zone), the regimen met its primary objective: 92% complete response (CR), 8% partial response, 100% overall response rate, one‑year PFS 91% and one‑year OS 100%. Investigators reported the combination was well tolerated; MRD evaluation and longer follow‑up were noted as next steps.
ALX Oncology (Nasdaq: ALXO) announced management will present at two investor conferences: a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 11:30 AM GMT / 6:30 AM EST, and a fireside chat at the Piper Sandler 37th Annual Global Healthcare Conference in New York on Dec 3, 2025 at 9:30 AM EST.
Both events will be webcast; live links are available in the Investors > Events and Presentations section at www.alxoncology.com. Replays of each webcast will be archived for up to 90 days after the presentation dates.
ALX Oncology (Nasdaq: ALXO) reported Q3 2025 results and a corporate update on Nov 7, 2025. Key clinical highlights from an ASPEN-06 exploratory analysis showed strong benefit for evorpacept in retained HER2-positive, CD47-high gastric cancer: ORR 65.0% vs 26.1%, median DOR 25.5 vs 8.4 months, PFS 18.4 vs 7.0 months (HR 0.39), and OS 17.0 vs 9.9 months (HR 0.63).
ALX remains on track to start Phase 2 ASPEN-09-Breast Cancer enrollment in Q4 2025 with interim data expected Q3 2026. Phase 1 ALX2004 is enrolling (dose cohort 2 at 2 mg/kg) with initial safety data expected in 1H 2026. Q3 cash, cash equivalents and investments were $66.5 million, funding operations into Q1 2027. The company appointed Barbara Klencke, M.D., as interim CMO and will host a webcast on Nov 7, 2025.
ALX Oncology (Nasdaq: ALXO) will report third quarter 2025 financial results and provide a business update on Friday, November 7, 2025 before market open, followed by a teleconference and live webcast at 5:30 a.m. PT / 8:30 a.m. ET.
The company said it will review upcoming data presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting highlighting a full data set showing CD47 overexpression as a potential predictive biomarker for response to evorpacept in HER2-positive gastric/gastroesophageal cancer. A poster (abstract 496) will be presented at SITC on November 8, 2025 and available as an eposter on November 7; presenter: Dr. Zev A. Wainberg.
Webcast and archived replay will be available on the company investor website.
ALX Oncology (NASDAQ: ALXO) presented preclinical data and the Phase 1 trial design for ALX2004, an EGFR-targeted antibody-drug conjugate, at the 2025 AACR-NCI-EORTC conference on October 23, 2025.
The company reported a robust preclinical package supporting differentiation in the EGFR-ADC class, described ALX2004’s matuzumab-derived EGFR antibody, proprietary Top1i payload and linker designed to improve on-target delivery and bystander effect, and confirmed the ongoing first-in-human study (NCT07085091) for advanced/metastatic EGFR-expressing solid tumors.
Enrollment began in August 2025 and initial safety data is anticipated in H1 2026.
ALX Oncology (Nasdaq: ALXO) will present updated Phase 2 ASPEN-06 data at the SITC 40th Annual Meeting (Nov 5–9, 2025) in National Harbor, MD. The poster reports that CD47 expression is a predictive biomarker for response to evorpacept in previously treated HER2-positive gastric and gastroesophageal junction cancer.
ASPEN-06 tested evorpacept combined with trastuzumab, ramucirumab, and paclitaxel. Poster details: Title "CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial," First Author Zev A. Wainberg, M.D., Abstract 496, presented Saturday, November 8, 2025, 10:00 a.m.–6:35 p.m. ET in Poster Hall (Exhibit Halls AB).
ALX Oncology (NASDAQ:ALXO) announced a significant leadership change as Dr. Barbara Klencke, a current board member, has been appointed as Interim Chief Medical Officer (CMO), replacing Dr. Alan Sandler who will return to his position on the company's Board of Directors.
Dr. Klencke brings over 30 years of experience in oncology and drug development, with notable achievements including serving as CMO at Sierra Oncology until its GSK acquisition in 2022. She will oversee the development of ALX's evorpacept and ALX2004 clinical programs, focusing on the company's CD47 blocker and EGFR-targeted antibody-drug conjugate (ADC) pipeline.